Recent multiomics studies from Accelerating Medicines Partnership for Alzheimer's Disease and Target Enablement to Accelerate Therapy Development for AD identified p21‐activated kinase 1 (PAK1) as a potential therapeutic target due to its aberrant activation in AD. The gene discussed is PAK1; the disease is early-onset autosomal dominant Alzheimer disease.